Related Experiment Video

Updated: Jul 4, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Pharmacogenetic pathway analysis of docetaxel elimination

S D Baker1, J Verweij, G A Cusatis

  • 1Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA. sharyn.baker@stjude.org

Clinical Pharmacology and Therapeutics
|May 30, 2008
PubMed

Insights

Docetaxel transport involves OATP1B3 (SLCO1B3) influx. The CYP3A4*1B and CYP3A5*1A haplotype significantly increases docetaxel clearance, suggesting a need for genotype-based stratification in future research.

Area of Science:

  • Pharmacology
  • Genetics
  • Drug Metabolism

Background:

  • Docetaxel is a key chemotherapy agent.
  • Understanding its transport and metabolism is crucial for optimizing treatment.
  • Genetic variations can influence drug efficacy and toxicity.

Purpose of the Study:

  • To investigate docetaxel's affinity for 14 transporter proteins.
  • To assess the functional impact of 17 genetic variants in five drug elimination genes.
  • To identify genetic factors influencing docetaxel clearance.

Main Methods:

  • In vitro studies using transfected cell models to assess transporter affinity.
  • Genotyping of SLCO1B3, ABCB1, ABCC2, CYP3A4, and CYP3A5 in 92 white patients.
  • Analysis of docetaxel and midazolam clearance.
  • Erythromycin breath test for CYP3A activity assessment.
  • Haplotype analysis of CYP3A locus in CEPH-HapMap samples.

Main Results:

  • OATP1B3 (SLCO1B3) demonstrated the highest docetaxel influx.
  • No significant association between SLCO1B3, ABCB1, or ABCC2 genotypes and docetaxel clearance.
  • The CYP3A4*1B and CYP3A5*1A haplotype correlated with a 64% increase in docetaxel clearance (P=0.0015).
  • This haplotype also increased midazolam clearance (P=0.0198).
  • CYP3A4*1B was found exclusively in a subset of CYP3A5 expressors.

Conclusions:

  • Docetaxel transport is mediated by OATP1B3.
  • The CYP3A4*1B/CYP3A5*1A haplotype is a significant predictor of increased docetaxel clearance.
  • Future studies should stratify populations by CYP3A5 genotype and CYP3A4*1B allele presence to better understand CYP3A activity.

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...